Author: Uzunova, Veselina V.; Todev, Angel; Zarkos, Jacqueline; Addai, Daniel; Ananiev, Julian; Rashev, Pavel; Alexandrova, Radostina; Tolekova, Anna
Title: Strengthening CoViD-19 therapy via combinations of RAS modulators Cord-id: sdy2badg Document date: 2021_3_25
ID: sdy2badg
Snippet: Evidence has accumulated that the pathology of CoViD-19 is strongly related to the renin-angiotensin system (RAS). The blockage of the angiotensin converting enzyme 2 (ACE2) by the SARS-CoV-2 virus leads to downstream consequences such as increased vascular tone, extensive fibrosis and pronounced immune reactions. Different approaches to tackle the adverse viral effects by compensating the lost ACE2 function have been suggested. Here, we use an unequal-arm lever model to describe a simplified ve
Document: Evidence has accumulated that the pathology of CoViD-19 is strongly related to the renin-angiotensin system (RAS). The blockage of the angiotensin converting enzyme 2 (ACE2) by the SARS-CoV-2 virus leads to downstream consequences such as increased vascular tone, extensive fibrosis and pronounced immune reactions. Different approaches to tackle the adverse viral effects by compensating the lost ACE2 function have been suggested. Here, we use an unequal-arm lever model to describe a simplified version of the biased regulation exercised by the angiotensin II and angiotensin-(1-7) hormones, which are the substrate and the product of ACE2, respectively. We reason upon the lever dynamics and its disruptions caused by the virus, and propose that a combination of RAS modulators will most efficiently compensate the imbalance due to the excess of angiotensin II and the scarcity of angiotensin-(1-7). Specifically, we focus on the possible benefits of the simultaneous application of two agents, a MAS-receptor agonist and an angiotensin-II-type-2-receptor agonist. We conjecture that this combination has the potential to introduce a beneficial synergistic action that promotes anti-hypoxic, anti-fibrotic and anti-proliferative effects, thereby improving the clinical management of acute and chronic CoViD-19 pathologies.
Search related documents:
Co phrase search for related documents- ace enzyme and acute organ damage: 1
- ace enzyme and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
- ace enzyme and lung liver: 1, 2, 3, 4
- ace enzyme and lung liver kidney: 1
- ace enzyme and lung pathology: 1, 2, 3, 4
- ace inhibitor and acute lung injury: 1, 2, 3, 4
- ace inhibitor and lung injury: 1, 2, 3, 4
- ace inhibitor and lung liver: 1
Co phrase search for related documents, hyperlinks ordered by date